MX2020002741A - Uso de gaboxadol en el tratamiento de narcolepsia. - Google Patents

Uso de gaboxadol en el tratamiento de narcolepsia.

Info

Publication number
MX2020002741A
MX2020002741A MX2020002741A MX2020002741A MX2020002741A MX 2020002741 A MX2020002741 A MX 2020002741A MX 2020002741 A MX2020002741 A MX 2020002741A MX 2020002741 A MX2020002741 A MX 2020002741A MX 2020002741 A MX2020002741 A MX 2020002741A
Authority
MX
Mexico
Prior art keywords
narcolepsy
gaboxadol
treatment
compositions
sub
Prior art date
Application number
MX2020002741A
Other languages
English (en)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of MX2020002741A publication Critical patent/MX2020002741A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Se proporcionan métodos y composiciones para tratar la narcolepsia que incluyen administrar gaboxadol o una sal farmacéuticamente aceptable del mismo a un paciente diagnosticado con narcolepsia. Asimismo, se proporcionan métodos y composiciones para tratar la narcolepsia que incluye administrar a un paciente que lo necesita, gaboxadol o una sal farmacéuticamente aceptable del mismo, en combinación con uno o más de un estimulante del SNC, un agente eugeroico, un antidepresivo o un agonista de receptores GABAB.
MX2020002741A 2017-09-12 2018-09-11 Uso de gaboxadol en el tratamiento de narcolepsia. MX2020002741A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762557412P 2017-09-12 2017-09-12
PCT/US2018/050339 WO2019055369A1 (en) 2017-09-12 2018-09-11 USE OF GABOXADOL IN THE TREATMENT OF NARCOLEPSIA

Publications (1)

Publication Number Publication Date
MX2020002741A true MX2020002741A (es) 2020-07-21

Family

ID=65630168

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002741A MX2020002741A (es) 2017-09-12 2018-09-11 Uso de gaboxadol en el tratamiento de narcolepsia.

Country Status (10)

Country Link
US (2) US20190076409A1 (es)
EP (1) EP3661507A4 (es)
JP (1) JP2020533415A (es)
KR (1) KR20200053570A (es)
CN (1) CN111328282A (es)
AU (1) AU2018331326A1 (es)
CA (1) CA3075478A1 (es)
IL (1) IL272962A (es)
MX (1) MX2020002741A (es)
WO (1) WO2019055369A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111328282A (zh) * 2017-09-12 2020-06-23 奥维德医疗公司 加波沙朵在治疗发作性睡病中的用途
EP3883566A4 (en) 2018-11-21 2022-09-07 Certego Therapeutics Inc. GABOXADOL FOR SUICIDE RISK REDUCTION AND RAPID DEPRESSION RELIEF
CN114008013A (zh) 2019-06-28 2022-02-01 哥本哈根大学 伴有睡眠障碍的cns病症的治疗
US11597726B2 (en) 2020-05-20 2023-03-07 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200528098A (en) * 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
WO2005063248A1 (en) * 2003-12-22 2005-07-14 Sepracor Inc. Modafinil combination therapy for improving sleep quality
US9480695B2 (en) * 2011-09-29 2016-11-01 The University Of Tokyo Methods for inducing orexin neurons and agent for treating narcolepsy or eating disorder
US9050302B2 (en) * 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
DK2968208T3 (da) * 2013-03-13 2022-08-22 Jazz Pharmaceuticals Ireland Ltd Behandling af kataplexi
US9682069B2 (en) * 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
CN109414435A (zh) * 2016-05-26 2019-03-01 奥维德医疗公司 使用哌苯甲醇治疗行为综合征的方法
CN111328282A (zh) * 2017-09-12 2020-06-23 奥维德医疗公司 加波沙朵在治疗发作性睡病中的用途

Also Published As

Publication number Publication date
IL272962A (en) 2020-04-30
EP3661507A1 (en) 2020-06-10
CN111328282A (zh) 2020-06-23
EP3661507A4 (en) 2020-11-18
US20200222372A1 (en) 2020-07-16
KR20200053570A (ko) 2020-05-18
WO2019055369A1 (en) 2019-03-21
AU2018331326A1 (en) 2020-03-19
US20190076409A1 (en) 2019-03-14
CA3075478A1 (en) 2019-03-21
JP2020533415A (ja) 2020-11-19

Similar Documents

Publication Publication Date Title
MX2020002741A (es) Uso de gaboxadol en el tratamiento de narcolepsia.
SA518391624B1 (ar) Ror- منظمات جاما
MX2017014192A (es) Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX2022007989A (es) Composiciones y metodos para tratar pterigion.
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
MX2022001075A (es) Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
MX2020012602A (es) Composiciones bacterianas dise?adas y usos de las mismas.
EA201791882A1 (ru) Агонисты 5ht для лечения нарушений
PH12020551425A1 (en) Rimegepant for cgrp related disorders
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
TW201713341A (en) Compositions and methods of treating a neurodegenerative disease
JOP20200230A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
MX2018004664A (es) Antagonistas de ep4.
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
TW201613578A (en) Pharmaceutical combinations
MX2018001720A (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos.
SI3348547T1 (sl) Derivati benzimidazola kot zaviralci NAV 1.7 (natrijevi kanalčki, napetostno odvisni, tip IX, podenota alfa (SCN9A)) za zdravljenje bolečine, disurije in multiple skleroze
EA201892311A1 (ru) Производные 2-анилинопиримидина в качестве терапевтических агентов для лечения рака мозга
MX2017009110A (es) Terapia de combinacion para hipertension pulmonar.
MX2020005864A (es) Inhibidores de dopamina-b-hidroxilasa.
PH12021550671A1 (en) Prodrugs of cgrp antagonists
EP2464355A4 (en) SUBSTITUTED TRIAZOLPHTHALAZINE DERIVATIVES